Clearmind Medicine (NASDAQ:CMND) Major Shareholder Financial Lp Hrt Sells 3,183 Shares

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt sold 3,183 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $3.32, for a total transaction of $10,567.56. Following the completion of the transaction, the insider directly owned 103,492 shares of the company’s stock, valued at approximately $343,593.44. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, June 12th, Financial Lp Hrt sold 2,102 shares of Clearmind Medicine stock. The shares were sold at an average price of $3.36, for a total transaction of $7,062.72.
• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The shares were sold at an average price of $0.12, for a total transaction of $27,022.92.
• On Wednesday, June 10th, Financial Lp Hrt bought 2,159,052 shares of Clearmind Medicine stock. The stock was bought at an average cost of $0.15 per share, with a total value of $323,857.80.

Clearmind Medicine Stock Performance

Shares of CMND remained flat at $3.14 during mid-day trading on Wednesday. 120,986 shares of the stock were exchanged, compared to its average volume of 1,140,760. The stock’s 50-day simple moving average is $5.92 and its 200-day simple moving average is $15.64. Clearmind Medicine Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $524.00. The company has a market cap of $3.20 million, a P/E ratio of -0.02 and a beta of 0.64.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings data on Monday, June 15th. The company reported ($6.78) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a research note on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.